A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Grifols Therapeutics LLC